Literature DB >> 2410171

Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection.

J Y Reginster, P Franchimont.   

Abstract

Side effects are the most frequent reason for discontinuing treatment with Calcitonin. Having been assessed in a previous report that the intranasal administration of Synthetic Salmon Calcitonin (SSCT) is as effective as its intramuscular administration, the aim of this work was to investigate the side-effects of intranasal administration of SSCT in patients who are known to show intolerance after intramuscular administration of the drug. The results show that intranasal administration of SSCT does not give rise to side-effects even in patients known to be intolerant to SSCT by the intramuscular route.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410171

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  16 in total

1.  Calcitonin effects on shoulder adhesive capsulitis.

Authors:  Alireza Rouhani; Mohsen Mardani-Kivi; Mohammadreza Bazavar; Mahmood Barzgar; Ali Tabrizi; Keyvan Hashemi-Motlagh; Khashayar Saheb-Ekhtiari
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-07-08

Review 2.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

3.  Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis.

Authors:  A Sileghem; P Geusens; J Dequeker
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

4.  Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.

Authors:  A E Pontiroli; E Pajetta; A Calderara; M Alberetto; G Pozza; V Manganelli; G Resmini; L Tessari; V Maresca
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

Review 5.  Calcitonin in the treatment of osteoporosis.

Authors:  C Gennari; A Camporeale
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

6.  Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.

Authors:  D González; E Vega; G Ghiringhelli; C Mautalen
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

Review 7.  Future horizons for calcitonin: a U.S. perspective.

Authors:  J H Carstens; J D Feinblatt
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 8.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

9.  The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Authors:  W A Lee; R D Ennis; J P Longenecker; P Bengtsson
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

10.  Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin.

Authors:  N G Schipper; J C Verhoef; S G Romeijn; F W Merkus
Journal:  Calcif Tissue Int       Date:  1995-04       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.